<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36564007</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1678-4782</ISSN><JournalIssue CitedMedium="Internet"><Volume>99 Suppl 1</Volume><Issue>Suppl 1</Issue><PubDate><Year>2023</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Jornal de pediatria</Title><ISOAbbreviation>J Pediatr (Rio J)</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccination in children: a public health priority.</ArticleTitle><Pagination><StartPage>S28</StartPage><EndPage>S36</EndPage><MedlinePgn>S28-S36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jped.2022.11.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-7557(22)00134-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Covid-19 had a direct impact on children's health. The aim of this review was to analyze epidemiological and clinical data, the consequences of the pandemic, and vaccination aspects in this group.</AbstractText><AbstractText Label="SOURCES OF DATA">The searches were carried out from January 2020 to November 2022, in the MEDLINE databases (PubMed) and publications of the Brazilian Ministry of Health and the Brazilian Society of Pediatrics.</AbstractText><AbstractText Label="SUMMARY OF FINDINGS">Covid-19 has a mild presentation in most children; however, the infection can progress to the severe form and, in some cases, to MIS-C. The prevalence of the so-called long Covid in children was 25.24%. Moreover, several indirect impacts occurred on the health of children and adolescents. Vaccination played a crucial role in enabling the reduction of severe disease and mortality rates. Children and adolescents, as a special population, were excluded from the initial clinical trials and, therefore, vaccination was introduced later in this group. Despite its importance, there have been difficulties in the efficient implementation of vaccination in the pediatric population. The CoronaVac vaccines are authorized in Brazil for children over three years of age and the pediatric presentations of the Pfizer vaccine have shown significant effectiveness and safety.</AbstractText><AbstractText Label="CONCLUSIONS">Covid-19 in the pediatric age group was responsible for the illness and deaths of a significant number of children. For successful immunization, major barriers have to be overcome. Real-world data on the safety and efficacy of several pediatric vaccines is emphasized, and the authors need a uniform message about the importance of immunization for all children.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>da Fonseca Lima</LastName><ForeName>Eduardo Jorge</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, PE, Brazil; Faculdade Pernambucana de Sa&#xfa;de (FPS), Recife, PE, Brazil. Electronic address: eduardojorge@imip.org.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Rob&#xe9;rio Dias</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, Departamento de Sa&#xfa;de da Mulher, da Crian&#xe7;a e do Adolescente, Fortaleza, CE, Brazil; Hospital S&#xe3;o Jos&#xe9; de Doen&#xe7;as Infecciosas da Secretaria de Sa&#xfa;de do Estado do Cear&#xe1;, Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>J Pediatr (Rio J)</MedlineTA><NlmUniqueID>2985188R</NlmUniqueID><ISSNLinking>0021-7557</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000722216">sinovac COVID-19 vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006292" MajorTopicYN="N">Health Priorities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 related</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">Myocarditis</Keyword><Keyword MajorTopicYN="N">Pediatric multisystem inflammatory disease</Keyword><Keyword MajorTopicYN="N">Vaccine adverse event</Keyword></KeywordList><CoiStatement>Conflicts of interest The authors declare no conflicts of interest Both authors occasionally act as guest speakers and consultants in laboratories in the area of vaccines.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>19</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36564007</ArticleId><ArticleId IdType="pmc">PMC9767816</ArticleId><ArticleId IdType="doi">10.1016/j.jped.2022.11.006</ArticleId><ArticleId IdType="pii">S0021-7557(22)00134-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Diseases Control and Prevention (CDC). COVID data tracker: demographic trends of COVID-19 cases and deaths in the US reported to CDC. [Cited 15 Nov 2022].Available from: https://covid.cdc.gov/Covid-data-tracker/#demographics.</Citation></Reference><Reference><Citation>Centers for Diseases Control and Prevention (CDC). COVID data tracker: demographic trends of COVID-19 cases and deaths in the US reported to CDC. Deaths by age group. [Cited 15 Nov 2022]. Available from: https://covid.cdc.gov/Covid-data-tracker/#demographics</Citation></Reference><Reference><Citation>Centers for Diseases Control and Prevention (CDC). Fluview interactive. Infuenza-associated pediatric mortality. [Cited 15 Nov 2022]. Available from: https://covid.cdc.gov/Covid-data-tracker/#datatracker-home.</Citation></Reference><Reference><Citation>World Health Organization (WHO). Interim statement on COVID-19 vaccination for children. [Cited 11 Nov 2022]. Available from: https://www.who.int/news/item/11-08-2022-interim-statement-on-covid-19-vaccination-for-children.</Citation></Reference><Reference><Citation>Kitano T, Kitano M, Krueger C, Jamal H, Al Rawahi H, Lee-Krueger R, et al. The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: a systematic review of fatality and ICU admission in children worldwide. PLoS One. 2021;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845974</ArticleId><ArticleId IdType="pubmed">33513204</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin AT, Owusu-Boaitey N, Pugh S, Fosdick BK, Zwi AB, Malani A, et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob Health. 2022;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9136695</ArticleId><ArticleId IdType="pubmed">35618305</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy B. Covid-19 mata dois menores de 5 anos por dia no Brasil. Ag&#xea;ncia Fiocruz de Notic&#xed;as. [Cited 10 Nov 2022]. Available from: https://portal.fiocruz.br/noticia/covid-19-mata-dois-menores-de-5-anos-por-dia-no-brasil.</Citation></Reference><Reference><Citation>Taylor L. Covid-19: Brazil is recording a fifth of all deaths of under 5s. BMJ. 2022;378:o1634.</Citation><ArticleIdList><ArticleId IdType="pubmed">35777758</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JH, Choi SH, Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci. 2022;37:e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8822112</ArticleId><ArticleId IdType="pubmed">35132841</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children. Pediatrics. 2022;149</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213563</ArticleId><ArticleId IdType="pubmed">34935038</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193431</ArticleId><ArticleId IdType="pubmed">34110391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyanaraman M, Anderson MR. COVID-19 in children. Pediatr Clin North Am. 2022;69:547&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8808705</ArticleId><ArticleId IdType="pubmed">35667761</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, et al. Risk for newly diagnosed diabetes &gt;30 days after SARS-CoV-2 infection among persons aged &lt;18 years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757617</ArticleId><ArticleId IdType="pubmed">35025851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendall EK, Olaker VR, Kaelber DC, Xu R, Davis PB. Association of SARS-CoV-2 infection with new-onset type 1 diabetes among pediatric patients from 2020 to 2021. JAMA Netw Open. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9508649</ArticleId><ArticleId IdType="pubmed">36149658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022;12:9950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nations Children's Fund (UNICEF). Where are we on education recovery. [Cited 10 Nov 2022]. Available from: https://www.unicef.org/lac/media/32546/file/Where-are-we-in-education-recovery.pdf.</Citation></Reference><Reference><Citation>Xu W, Li X, Dozier M, He Y, Kirolos A, Lang Z, et al. What is the evidence for transmission of COVID-19 by children in schools? A living systematic review. J Glob Health. 2020;10 021104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7774027</ArticleId><ArticleId IdType="pubmed">33437465</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajmil L. Role of children in the transmission of the COVID-19 pandemic: a rapid scoping review. BMJ Paediatr Open. 2020;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311007</ArticleId><ArticleId IdType="pubmed">32596514</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverberg SL, Zhang BY, Li SN, Burgert C, Shulha HP, Kitchin V, et al. Child transmission of SARS-CoV-2: a systematic review and meta-analysis. BMC Pediatr. 2022;22:172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8975734</ArticleId><ArticleId IdType="pubmed">35365104</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paris K, Permar SR. Routine SARS-CoV-2 vaccination for all children. Immunol Rev. 2022;309:90&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9339529</ArticleId><ArticleId IdType="pubmed">35799475</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Pittet LF, Finn A, Pollard AJ, Curtis N. Should children be vaccinated against COVID-19? Arch Dis Child. 2022;107:e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">34732388</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmiche S, Charmet T, Schaeffer L, Paireau J, Grant R, Ch&#xe9;ny O, et al. Exposures associated with SARS-CoV-2 infection in France: a nationwide online case-control study. Lancet Reg Health Eur. 2021;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183123</ArticleId><ArticleId IdType="pubmed">34124709</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing QL, Liu MJ, Zhang ZB, Fang LQ, Yuan J, Zhang AR, et al. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. Lancet Infect Dis. 2020;20:1141&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7529929</ArticleId><ArticleId IdType="pubmed">32562601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian F, Yang R, Chen Z. Safety and efficacy of COVID-19 vaccines in children and adolescents: a systematic review of randomized controlled trials. J Med Virol. 2022;94:4644&#x2013;4653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350282</ArticleId><ArticleId IdType="pubmed">35705969</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasil. Minist&#xe9;rio da Sa&#xfa;de. Ag&#xea;ncia Nacional de Vigil&#xe2;ncia Sanit&#xe1;ria - Anvisa. Covid-19: Anvisa aprova vacina da Pfizer para crian&#xe7;as entre 6 meses e 4 anos. Bras&#xed;lia, 2022. [Cited 13 Nov 2022]. Available from: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2022/covid-19-anvisa-aprova-vacina-da-pfizer-para-criancas-entre-6-meses-e-4-anos.</Citation></Reference><Reference><Citation>Brasil. Minist&#xe9;rio da Sa&#xfa;de. Secretaria de Vigil&#xe2;ncia em Sa&#xfa;de. Departamento de Imuniza&#xe7;&#xe3;o e Doen&#xe7;as Transmiss&#xed;veis. Plano Nacional de Operacionaliza&#xe7;&#xe3;o da Vacina&#xe7;&#xe3;o contra a Covid-19. Bras&#xed;lia, 2022. [Cited 11 Nov 2022]. Available from: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/publicacoes-svs/coronavirus/plano-nacional-de-operacionalizacao-da-vacinacao-contra-a-covid-19-pno-2a-edicao-com-isbn.</Citation></Reference><Reference><Citation>Brasil. Minist&#xe9;rio da Sa&#xfa;de. Secretaria de Vigil&#xe2;ncia em Sa&#xfa;de. Departamento de Imuniza&#xe7;&#xe3;o e Doen&#xe7;as Transmiss&#xed;veis. Coordena&#xe7;&#xe3;o-Geral do Programa Nacional de Imuniza&#xe7;&#xf5;es. NOTA T&#xc9;CNICA N&#xba; 213/2022-CGPNI/DEIDT/SVS/MS. Bras&#xed;lia, 2022. [Cited 11 Nov 2022]. Available from: https://www.gov.br/saude/pt-br/coronavirus/vacinas/plano-nacional-de-operacionalizacao-da-vacina-contra-a-covid-19/notas-tecnicas/2022/nota-tecnica-213-2022-cgpni-deidt-svs-ms.</Citation></Reference><Reference><Citation>Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci Transl Med. 2020;12:eabd5487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7658796</ArticleId><ArticleId IdType="pubmed">32958614</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau EH, Tsang OT, Hui DS, Kwan MY, Chan W, Chiu SS, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021;12:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7782739</ArticleId><ArticleId IdType="pubmed">33397909</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Obregon-Perko V, Lapp SA, Horner AM, Brooks A, Macoy L, et al. Limited induction of SARS-CoV-2-specific T cell responses in children with multisystem inflammatory syndrome compared with COVID-19. JCI Insight. 2022;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8876428</ArticleId><ArticleId IdType="pubmed">35044955</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Jin P, Zhu T, Wang W, Ye H, Pan H, et al. Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis. 2022;75:e783&#x2013;e791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522421</ArticleId><ArticleId IdType="pubmed">34551104</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Chen L, Shi Y. Safety, immunogenicity, and efficacy of COVID-19 vaccines in adolescents, children, and infants: a systematic review and meta-analysis. Front Public Health. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046659</ArticleId><ArticleId IdType="pubmed">35493393</ArticleId></ArticleIdList></Reference><Reference><Citation>Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:1645&#x2013;1653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238449</ArticleId><ArticleId IdType="pubmed">34197764</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, et al. Effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 Years - United States, June-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1483&#x2013;1488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9361838</ArticleId><ArticleId IdType="pubmed">34673751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;385:2241&#x2013;2251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385554</ArticleId><ArticleId IdType="pubmed">34379915</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5&#x2013;11 years and adolescents aged 12&#x2013;15 years &#x2014; PROTECT Cohort, July 2021&#x2013;February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:422&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942308</ArticleId><ArticleId IdType="pubmed">35298453</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Diseases Control and Prevention &#x2013; CDC. Science brief: transmission of SARS-CoV-2 in K-12 schools. [Cited 11 Nov 2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/transmission_k_12_schools.html</Citation><ArticleIdList><ArticleId IdType="pubmed">34009772</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Diseases Control and Prevention. Covid data tracker: case &amp; death trends by demographics. [Cited 11 Nov 2022]. Available from: https://covid.cdc.gov/covid-data-tracker/#cases-deaths-trends-by-demographic.</Citation></Reference><Reference><Citation>Centers for Diseases Control and Prevention. Advisory Committee on Immunization Practices (ACIP) meeting June, 2022. Coronavirus disease 2019 (Covid-19) vaccines. [Cited 11 Nov 2022]. Available from: https://www.cdc.gov/vaccines/acip/index.html</Citation></Reference><Reference><Citation>Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12&#x2013;18 Years &#x2014; United States, July&#x2013;December 2021. MMWR Morb Mortal Wkly Rep. 2022;71:52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757620</ArticleId><ArticleId IdType="pubmed">35025852</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11&#x2009;years of age. N Engl J Med. 2022;386:35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, et al. Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11&#x2009;years of age. N Engl J Med. 2022;386:2011&#x2013;2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127699</ArticleId><ArticleId IdType="pubmed">35544369</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JR; CDC COVID-19 Vaccine Task Force. Vaccine Safety Team. Adverse events among children ages 5&#x2013;11 years after Covid-19 vaccination: updates from v-safe and the Vaccine Adverse Event Reporting System (VAERS). Awardee Covid-19 Vaccination Planning Meeting; December 2021. [Cited 11 Nov 2022]. Available from: https://stacks.cdc.gov/view/cdc/112668</Citation></Reference><Reference><Citation>Brasil. Minist&#xe9;rio da Sa&#xfa;de. Ag&#xea;ncia Nacional de Vigil&#xe2;ncia Sanit&#xe1;ria - Anvisa. Covid-19: Anvisa aprova vacina da Pfizer para crian&#xe7;as entre 6 meses e 4 anos. Bras&#xed;lia, 2022. [Cited 11 Nov 2022]. Available from: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2022/covid-19-anvisa-aprova-vacina-da-pfizer-para-criancas-entre-6-meses-e-4-anos.</Citation></Reference><Reference><Citation>Constantino, C. F., Cunha, J., Kfouri, R. A. Posicionamento das Sociedades Brasileiras de Pediatria (SBP) e de Imuniza&#xe7;&#xf5;es (SBIm). Sociedades Brasileiras de Pediatria (SBP) e de Imuniza&#xe7;&#xf5;es (SBIm). [Cited 11 Nov 2022]. Available from:https://www.sbp.com.br/fileadmin/user_upload/sbp/2022/novembro/16/23806c-NE</Citation></Reference><Reference><Citation>Jara A, Undurraga EA, Zubizarreta JR, Gonz&#xe1;lez C, Acevedo J, Pizarro A, et al. Effectiveness of CoronaVac in children 3&#x2013;5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. Nat Med. 2022;28:1377&#x2013;1380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307483</ArticleId><ArticleId IdType="pubmed">35605637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, et al. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study. Lancet Reg Health Eur. 2022;17 Erratum in: Lancet Reg Health Eur. 2022;21:100468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9051933</ArticleId><ArticleId IdType="pubmed">35505833</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U, Holm M, Hartling UB, Glenth&#xf8;j J, Schmidt LS, Nordly SB, et al. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. Lancet Child Adolesc Health. 2022;6:459&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9072929</ArticleId><ArticleId IdType="pubmed">35526537</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles ML, Gunatilaka A, Palmer K, Sharma K, Roach V. Alignment of national COVID-19 vaccine recommendations for pregnant and lactating women. Bull World Health Organ. 2021;99:739&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8477428</ArticleId><ArticleId IdType="pubmed">34621092</ArticleId></ArticleIdList></Reference><Reference><Citation>Shook LL, Fallah PN, Silberman JN, Edlow AG. COVID-19 vaccination in pregnancy and lactation: current research and gaps in understanding. Front Cell Infect Microbiol. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8481914</ArticleId><ArticleId IdType="pubmed">34604115</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AA, Chemaitelly H, Al Khal A, Coyle PV, Saleh H, Kaleeckal AH, et al. SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. J Clin Invest. 2021;131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631593</ArticleId><ArticleId IdType="pubmed">34618693</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier AY, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA. 2021;325:2370&#x2013;2380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8120446</ArticleId><ArticleId IdType="pubmed">33983379</ArticleId></ArticleIdList></Reference><Reference><Citation>Beharier O, Plitman Mayo R, Raz T, Nahum Sacks K, Schreiber L, Suissa-Cohen Y, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest. 2021;131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8483743</ArticleId><ArticleId IdType="pubmed">34596052</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks KJ, Whitaker M, Agathis NT, Anglin O, Milucky J, Patel K, et al. Hospitalization of infants and children aged 0&#x2013;4 years with laboratory-confirmed COVID-19 &#x2014; COVID-NET, 14 states, March 2020&#x2013;February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:429&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942304</ArticleId><ArticleId IdType="pubmed">35298458</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhu M, Murphy EA, Sukhu AC, Yee J, Singh S, Eng D, et al. Antibody Response to Coronavirus Disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood. Obstet Gynecol. 2021;138:278&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8288193</ArticleId><ArticleId IdType="pubmed">33910219</ArticleId></ArticleIdList></Reference><Reference><Citation>Beharier O, Plitman Mayo R, Raz T, Nahum Sacks K, Schreiber L, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest. 2021;131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8483743</ArticleId><ArticleId IdType="pubmed">34596052</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021;225 303.e1-303.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997025</ArticleId><ArticleId IdType="pubmed">33775692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CT, Chin SC, Chu PH. Acute fulminant myocarditis after ChAdOx1 nCoV-19 vaccine: a case report and literature review. Front Cardiovasc Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9068965</ArticleId><ArticleId IdType="pubmed">35528839</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaduzzaman M, Purkayastha B, Alam MM, Chakraborty SR, Roy S, Ahmed N. COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: a case report. J Neuroimmunol. 2022;368</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9080027</ArticleId><ArticleId IdType="pubmed">35561428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed SK. Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: a report of 7 cases. Ann Med Surg (Lond) 2022;77</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021031</ArticleId><ArticleId IdType="pubmed">35479661</ArticleId></ArticleIdList></Reference><Reference><Citation>Witberg G, Magen O, Hoss S, Talmor-Barkan Y, Richter I, Wiessman M, et al. Myocarditis after BNT162b2 vaccination in Israeli adolescents. N Engl J Med. 2022;77:1816&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9634859</ArticleId><ArticleId IdType="pubmed">36260842</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadley SM, Prakash A, Baker AL, de Ferranti SD, Newburger JW, Friedman KG, Dionne A. Follow-up cardiac magnetic resonance in children with vaccine-associated myocarditis. Eur J Pediatr. 2022;18:2879&#x2013;2883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046711</ArticleId><ArticleId IdType="pubmed">35482094</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel T, Kelleman M, West Z, Peter A, Dove M, Butto A, Oster ME. Comparison of multisystem inflammatory syndrome in children-related myocarditis, classic viral myocarditis, and COVID-19 vaccine-related myocarditis in children. J Am Heart Assoc. 2022;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9238597</ArticleId><ArticleId IdType="pubmed">35475362</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2022;22:196&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443232</ArticleId><ArticleId IdType="pubmed">34536349</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasil. Minist&#xe9;rio da Sa&#xfa;de. Secretaria de Vigil&#xe2;ncia em Sa&#xfa;de. Departamento de Imuniza&#xe7;&#xe3;o e Doen&#xe7;as Transmiss&#xed;veis. Plano Nacional de Operacionaliza&#xe7;&#xe3;o da Vacina&#xe7;&#xe3;o contra a Covid-19. 2&#xaa;.edi&#xe7;&#xe3;o. Bras&#xed;lia, 2022. [Cited 11 Nov 2022]. Available from:https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/publicacoes-svs/coronavirus/plano-nacional-de-operacionalizacao-da-vacinacao-contra-a-covid-19-pno-2a-edicao-com-isbn.</Citation></Reference><Reference><Citation>Lima EJ, Faria SM, Kfouri RA. Reflections on the use of COVID-19 vaccines in children and adolescents. Epidemiol Serv Saude. 2021;30 English, Portuguese.</Citation><ArticleIdList><ArticleId IdType="pubmed">34932771</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran Kiem C, Massonnaud CR, Levy-Bruhl D, Poletto C, Colizza V, Bosetti P, et al. A modelling study investigating short and medium-term challenges for COVID-19 vaccination: from prioritisation to the relaxation of measures. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278244</ArticleId><ArticleId IdType="pubmed">34278284</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell FM, Greenwood B. Who should be prioritised for COVID-19 vaccination? Hum Vaccin Immunother. 2021;17:1317&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078651</ArticleId><ArticleId IdType="pubmed">33141000</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souza TH, Nadal JA, Nogueira RJN, Pereira RM, Brand&#xe3;o MB. Clinical manifestations of children with COVID-19: a systematic review. Pediatr Pulmonol. 2020;55:1892&#x2013;1899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300659</ArticleId><ArticleId IdType="pubmed">32492251</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Curtis N. Why is COVID-19 less severe in children? a review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. 2020 doi: 10.1136/archdischild-2020-320338. archdischild-2020-320338Epub ahead of print. PMID: 33262177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2020-320338</ArticleId><ArticleId IdType="pubmed">33262177</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard-Rohner G, Didierlaurent A, Tilmanne A, Smeesters P, Marchant A. Pediatric COVID-19: immunopathogenesis, transmission and prevention. Vaccines. 2021;9:1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8473426</ArticleId><ArticleId IdType="pubmed">34579240</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerda AA, Garc&#xed;a LY. Hesitation and refusal factors in individuals' decision-making processes regarding a coronavirus disease 2019 vaccination. Front Public Health. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096991</ArticleId><ArticleId IdType="pubmed">33968880</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerda AA, Garc&#xed;a LY. Factors explaining the fear of being infected with COVID-19. Health Expect. 2022;25:506&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239863</ArticleId><ArticleId IdType="pubmed">33974721</ArticleId></ArticleIdList></Reference><Reference><Citation>Cauchemez S, Bosetti P, Kiem CT, Mouro V, Consoli A, Fontanet A. Education and mental health: good reasons to vaccinate children. Lancet. 2021;398:387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279961</ArticleId><ArticleId IdType="pubmed">34273293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>